Cultures, products and methods using umbilical cord matrix cells

• US 8,268,302 B2
• Filed: 05/04/2010
• Issued: 09/18/2012
• Est. Priority Date: 02/25/2002
• Status: Expired due to Term

• Current Assignee: Kansas State University Research Foundation
• Original Assignee: Kansas State University Research Foundation
• Inventors: Weiss, Mark L., Davis, Duane, Mitchell, Kathy E., Troyer, Daryl L.
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US12/773,427
• Publication Number:
  US 20100284978A1
• Time in Patent Office: 868 Days
• Field of Search: 424/93.1, 424/93.21, 435/325
• US Class Current: 424/93.1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/62 DMSO
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2506/1369 from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0619 Neurons

Abstract

Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source. The technology can have application to any amniotic animal, including agricultural and laboratory animals and humans. The invention relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment.

Claims

1. A method of reducing motor dysfunction associated with Parkinson'"'"'s disease in a patient with Parkinson'"'"'s disease comprising:

a) enzymatically dispersing umbilical cord matrix to provide enzymatically dispersed umbilical cord matrix cells;

b) culturing the enzymatically dispersed umbilical cord matrix cells in the presence of epidermal growth factor (EGF) and platelet derived growth factor (PDGF) to proliferate the umbilical cord matrix cells;

c) culturing the enzymatically dispersed umbilical cord matrix cells on a substrate surface and removing non-adherent cells;

d) culturing adherent cells from (c) to select for a population of umbilical cord matrix cells that comprise cells that are negative for CD34 and CD45, positive for telomerase activity, can be expanded in vitro, and maintained in culture through repeated passages;

e) isolating the adherent cells from d);

f) introducing the isolated adherent cells from e) into the substantia nigra region of the midbrain striatum in a patient with Parkinson'"'"'s disease, and

g) allowing the cells to integrate into the substantia nigra region of the midbrain striatum of the patient whereby motor dysfunction associated with Parkinson'"'"'s disease in the patient is reduced.

2. The method of claim 1, wherein the umbilical cord matrix cells comprise a foreign gene.